Skip to main content
. 2017 Aug 9;7:7629. doi: 10.1038/s41598-017-07883-5

Table 1.

Baseline and intraoperative characteristics of patients.

RIPC (n = 11) sham (n = 11) p-value
demographics
age (years) 64.5 ± 2.6 65.5 ± 3.0 0.802
sex (male) 10 10 1.000
body weight (kg) 79.5 ± 5.2 89.9 ± 5.1 0.169
risk factors and co-morbidities
diabetes mellitus 0 1 0.500
hypertension 7 10 0.311
hyperlipidemia 3 7 0.114
peripheral vessel disease 1 1 1.000
COPD 1 1 1.000
renal disease (creatinine > 200 μmol/l) 3 1 0.586
cardiac status
angina CCS III–IV 5 4 1.000
previous myocardial infarction 2 3 1.000
left ventricular ejection fraction (%) 47.6 ± 2.7 47.7 ± 2.2 0.959
medication
aspirin 11 9 0.477
clopidogrel 3 5 0.421
β blockers 7 11 0.090
statins 7 11 0.090
ACE inhibitors or ARBs 7 9 0.635
risk scores
additive EuroSCORE 4.2 ± 0.5 4.6 ± 0.4 0.517
logistic EuroSCORE (%) 3.4 ± 0.7 3.7 ± 0.5 0.660
EuroSCORE II (%) 1.0 ± 0.1 1.1 ± 0.1 0.566
intraoperative characteristics
time from end of RIPC/sham to reperfusion (min) 141.9 ± 14.1 129.2 ± 5.7 0.413
aortic cross-clamp duration (min) 60.5 ± 6.5 73.5 ± 6.4 0.163
cardioplegia (ml) 1512 ± 69 1600 ± 65 0.373
reperfusion time (min) 30.9 ± 3.7 38.5 ± 4.8 0.230
number of bypass grafts 2.6 ± 0.3 3.4 ± 0.3 0.080
number of distal anastomoses 2.7 ± 0.2 3.3 ± 0.3 0.091
transit time graft flow (ml/min) 76.3 ± 11.0 81.5 ± 10.2 0.734

Data are mean ± standard error of the mean or number. Patient baseline and intraoperative characteristics were compared using unpaired Student’s t-test (continuous data) and 2-tailed Fisher’s exact test (categorical data). Chronic obstructive pulmonary disease (COPD), Canadian cardiovascular society score (CCS), angiotensin-converting enzyme (ACE), angiotensin-II-receptor blockers (ARBs), European system for cardiac operative risk evaluation (EuroSCORE), remote ischemic preconditioning (RIPC). Reperfusion time: time from release of aortic cross-clamp to end of cardiopulmonary bypass.